Vaccines (Nov 2021)

The Differences in the Level of Anti-SARS-CoV-2 Antibodies after mRNA Vaccine between Convalescent and Non-Previously Infected People Disappear after the Second Dose—Study in Healthcare Workers Group in Poland

  • Joanna Kwiecińska-Piróg,
  • Jana Przekwas,
  • Zuzanna Kraszewska,
  • Alicja Sękowska,
  • Sylwia Brodzka,
  • Natalia Wiktorczyk-Kapischke,
  • Katarzyna Grudlewska-Buda,
  • Ewa Wałecka-Zacharska,
  • Maciej Zacharski,
  • Aneta Mańkowska-Cyl,
  • Eugenia Gospodarek-Komkowska,
  • Krzysztof Skowron

DOI
https://doi.org/10.3390/vaccines9121402
Journal volume & issue
Vol. 9, no. 12
p. 1402

Abstract

Read online

(1) Background: In many infections, antibodies play a crucial role in controlling infection. In COVID-19, the dynamics of the immune system response to SARS-CoV-2 is not fully understood. (2) Methods: The study was conducted on 120 healthcare workers from Dr. Antoni Jurasz University Hospital No. 1 in Bydgoszcz, between June and December 2020. In all participants, IgA and IgG antibody serum concentrations were measured using the semi-quantitative Anti-SARS-CoV-2 ELISA test (Euroimmun). After vaccination, in January and February 2021, antibody levels were examined using the quantitative IgG Anti-SARS-CoV-2 Quantivac ELISA test (Euroimmun). (3) Results: During the whole study period, the SARS-CoV-2 infection was confirmed in 29 (24.2%) participants. In all infected participants, IgA and IgG antibodies were detectable after infection by semi-quantitative serological tests. Levels of antibodies were higher one month after the first dose in the convalescents than in the non-previously infected participants. In this second group, the level of antibodies increased significantly after the second dose of vaccines compared to the first dose. (4) Conclusions: The level of antibodies after the first dose of vaccine in the convalescents’ group is higher than in the SARS-CoV-2 non-infected group, but the differences disappear after the second vaccination.

Keywords